Cyanotic heart defect medical therapy

	Cyanotic heart defect Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cyanotic heart defect from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiography
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cyanotic heart defect medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cyanotic heart defect medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cyanotic heart defect medical therapy
CDC on Cyanotic heart defect medical therapy
Cyanotic heart defect medical therapy in the news
Blogs on Cyanotic heart defect medical therapy
Directions to Hospitals Treating Cyanotic heart defect
Risk calculators and risk factors for Cyanotic heart defect medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor(s)-In-Chief: Keri Shafer, M.D. [2], Atif Mohammad, M.D.

Overview

Infants that remain in the hospital may receive medicines to:

Get rid of extra fluids
Help the heart pump harder
Treat abnormal heartbeats or rhythms
In infants with severe polycythemia (>70 percent), an isovolumetric partial exchange transfusion should be performed with saline to reduce the hematocrit
Prostaglandin E1 (alprostadil) — Administered in infants with clinical suspicion of ductal-dependent congenital heart defect until a definitive diagnosis or treatment is established.